Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

Date publication

août 2021

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe

Tous les auteurs :
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Bono J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34450475

Résumé

There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD study (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and OS versus abiraterone or enzalutamide in patients with mCRPC previously treated with docetaxel and the alternative androgen-receptor-targeted agent (ARTA). Here, we investigated NLR as a biomarker.

Mots clés

abiraterone, cabazitaxel, enzalutamide, metastatic castration-resistant prostate cancer, neutrophil-to-lymphocyte ratio, prognostic factor

Référence

ESMO Open. 2021 Aug 24;6(5):100241